Figure 2.
Outcomes in the whole cohort and by FLT3-ITD status. (A) OS and (B) EFS in patients treated with venetoclax combinations. (C) OS and (D) EFS depending on FLT3-ITD status at diagnosis.

Outcomes in the whole cohort and by FLT3-ITD status. (A) OS and (B) EFS in patients treated with venetoclax combinations. (C) OS and (D) EFS depending on FLT3-ITD status at diagnosis.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal